

Paweł, Madej

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5481122/publications.pdf>

Version: 2024-02-01

38
papers

600
citations

687335

13
h-index

642715

23
g-index

39
all docs

39
docs citations

39
times ranked

892
citing authors

#	ARTICLE	IF	CITATIONS
1	Prediction of Insulin Resistance and Impaired Fasting Glucose Based on Sex Hormone-Binding Globulin (SHBG) Levels in Polycystic Ovary Syndrome. <i>International Journal of Endocrinology</i> , 2022, 2022, 1-6.	1.5	4
2	The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4334.	4.1	30
3	The Activity of Superoxide Dismutase, Its Relationship with the Concentration of Zinc and Copper and the Prevalence of rs2070424 Superoxide Dismutase Gene in Women with Polycystic Ovary Syndrome—Preliminary Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 2548.	2.4	9
4	Evaluation of Pro/Antioxidant Imbalance in Blood of Women with Polycystic Ovary Syndrome Based on Determination of Oxidized Low-Density Lipoproteins and Ferric Reducing Ability of Plasma Values. <i>Biomedicines</i> , 2022, 10, 1564.	3.2	4
5	Fresh insight into premature ovarian insufficiency. <i>Ginekologia Polska</i> , 2021, 92, 518-524.	0.7	5
6	The role of proprotein convertase subtilisin/kexin type-9 concentration and paraoxonase 1 activities in the blood of women with polycystic ovary syndrome. <i>Environmental Toxicology and Pharmacology</i> , 2021, 84, 103612.	4.0	3
7	The Associations between Sex Hormones and Lipid Profiles in Serum of Women with Different Phenotypes of Polycystic Ovary Syndrome. <i>Journal of Clinical Medicine</i> , 2021, 10, 3941.	2.4	9
8	Body Composition and Its Impact on the Hormonal Disturbances in Women with Polycystic Ovary Syndrome. <i>Nutrients</i> , 2021, 13, 4217.	4.1	4
9	The Influence of Treated and Untreated Subclinical Hypothyroidism on Metabolic Profile in Women with Polycystic Ovary Syndrome. <i>International Journal of Endocrinology</i> , 2021, 2021, 1-9.	1.5	7
10	Pentraxin 3 Levels in Young Women with and without Polycystic Ovary Syndrome (PCOS) in relation to the Nutritional Status and Systemic Inflammation. <i>International Journal of Endocrinology</i> , 2020, 2020, 1-7.	1.5	8
11	Zinc, copper, sirtuin 1 concentration, and glucose metabolism parameters in the blood of women with polycystic ovary syndrome. <i>Gynecological Endocrinology</i> , 2020, 36, 951-954.	1.7	5
12	In Search of New Therapeutics—Molecular Aspects of the PCOS Pathophysiology: Genetics, Hormones, Metabolism and Beyond. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7054.	4.1	36
13	Estradiol/testosterone and estradiol/androstenedione indexes and nutritional status in PCOS women — A pilot study. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2019, 242, 166-169.	1.1	14
14	Pentraxin 3 as a marker of endothelial dysfunction in young women with polycystic ovary syndrome (PCOS). <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2019, 79, 419-423.	1.2	6
15	The impact of sex hormones and metabolic markers on depressive symptoms and cognitive functioning in PCOS patients. <i>Gynecological Endocrinology</i> , 2019, 35, 965-969.	1.7	9
16	The correlation between the concentration of hepcidin in serum and the occurrence of insulin resistance and hyperandrogenemia in women with polycystic ovary syndrome. <i>European Review for Medical and Pharmacological Sciences</i> , 2018, 22, 7379-7384.	0.7	1
17	Daytime decrease of prolactin levels is associated with PCOS regardless to nutritional status and other hormones levels. <i>Gynecological Endocrinology</i> , 2017, 33, 336-341.	1.7	6
18	Personality type influence the gestational weight gain. <i>Gynecological Endocrinology</i> , 2017, 33, 625-628.	1.7	0

#	ARTICLE	IF	CITATIONS
19	The role of aquaporins in polycystic ovary syndrome – A way towards a novel drug target in PCOS. <i>Medical Hypotheses</i> , 2017, 102, 23-27.	1.5	7
20	Evaluation of Adipokines, Inflammatory Markers, and Sex Hormones in Simple and Complex Breast Cysts™ Fluid. <i>Disease Markers</i> , 2016, 2016, 1-6.	1.3	2
21	Hypogonadism and Sex Steroid Replacement Therapy in Girls with Turner Syndrome. <i>Journal of Pediatric and Adolescent Gynecology</i> , 2016, 29, 542-550.	0.7	11
22	Serum Anti-Müllerian Hormone Concentration in Young Women with Chronic Kidney Disease on Hemodialysis, and After Successful Kidney Transplantation. <i>Kidney and Blood Pressure Research</i> , 2016, 41, 552-560.	2.0	21
23	Sleep disturbances in women with polycystic ovary syndrome. <i>Gynecological Endocrinology</i> , 2016, 32, 1014-1017.	1.7	24
24	Circulating anti-Müllerian hormone levels in relation to nutritional status and selected adipokines levels in polycystic ovary syndrome. <i>Clinical Endocrinology</i> , 2015, 83, 98-104.	2.4	35
25	Circulating FGF21 levels are related to nutritional status and metabolic but not hormonal disturbances in polycystic ovary syndrome. <i>European Journal of Endocrinology</i> , 2015, 172, 173-179.	3.7	18
26	Plasma omentin and adiponectin levels as markers of adipose tissue dysfunction in normal weight and obese women with polycystic ovary syndrome. <i>Clinical Endocrinology</i> , 2014, 81, 529-535.	2.4	35
27	Circulating apelin level in relation to nutritional status in polycystic ovary syndrome and its association with metabolic and hormonal disturbances. <i>Clinical Endocrinology</i> , 2013, 79, 238-242.	2.4	50
28	Psychological Disturbances and Quality of Life in Obese and Infertile Women and Men. <i>International Journal of Endocrinology</i> , 2012, 2012, 1-14.	1.5	18
29	Are plasma levels of visfatin and retinol-binding protein 4 (RBP4) associated with body mass, metabolic and hormonal disturbances in women with polycystic ovary syndrome?. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2012, 162, 55-61.	1.1	28
30	Is the plasma anti-Müllerian hormone (AMH) level associated with body weight and metabolic, and hormonal disturbances in women with and without polycystic ovary syndrome?. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2011, 158, 254-259.	1.1	94
31	Processes of apoptosis and cell proliferation in uterine myomas originating from reproductive and perimenopausal women. <i>Folia Histochemica Et Cytobiologica</i> , 2011, 49, 398-404.	1.5	7
32	The TRAF2 and TRAF6 expression in myomas and myometrium of women in reproduction and perimenopausal age.. <i>Folia Histochemica Et Cytobiologica</i> , 2010, 48, 407-16.	1.5	7
33	The aromatase expression in myomas and myometriums of women in reproduction and perimenopausal age.. <i>Folia Histochemica Et Cytobiologica</i> , 2010, 47, 497-504.	1.5	5
34	Immunohistochemical localization of telomerase in myomas and in uterine myometrium. <i>Pathology Research and Practice</i> , 2008, 204, 637-642.	2.3	2
35	Is the polycystic ovary syndrome associated with chronic inflammation per se?. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2007, 133, 197-202.	1.1	51
36	Ozone Therapy in Induced Endotoxemic Shock. II. The Effect of Ozone Therapy Upon Selected Histochemical Reactions in Organs of Rats in Endotoxemic Shock. <i>Inflammation</i> , 2007, 30, 69-86.	3.8	18

#	ARTICLE	IF	CITATIONS
37	Nucleolar organizer regions (NORs) in adenomyosis. Pathology Research and Practice, 2006, 202, 433-437.	2.3	4
38	Evaluation of nucleolar organizer region (NOR) parameters in the uterine leiomyoma. Pathology Research and Practice, 2005, 201, 587-592.	2.3	2